BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Bioventus Inc.

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$13.49+0.19 (+1.43%)

Close on Oct 19, 2026

Market cap: $955.61M
P/E (TTM): 17.5
Dividend yield: –

Dividends

Bioventus has not reported a dividend

No dividend per share appears in Bioventus's annual filings since fiscal 2018.

Where these numbers come from

Parsed from the XBRL in Bioventus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BVS.

Revenue growth3.1% · median 13.9%

Gross margin68.7% · median 68.5%

Operating margin10.0% · median 2.3%

Net margin9.4% · median -0.7%

Company	Revenue	Growth
GMED	$3.14B	+19.7%
OFIX	$833.19M	+3.0%
BVS	$581.85M	+3.1%
ATRC	$569.62M	+13.9%
AORT	$471.47M	+16.4%
ANIK	$120.65M	+5.3%

Company

Next earnings (est.): Nov 3, 2026, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 930
Held by institutions: 71.2%
Auditor: GRANT THORNTON LLP
SEC CIK: 1665988

Advertisement
300 × 250